‘Digoxin conundrum – Time for validation?’

Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs. However, there is some light at the end of the tunnel for Digoxin, with the reporting of RATE-AF Trial at the recent Europea...

Descripción completa

Detalles Bibliográficos
Autor principal: Yadava, O.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Opinion Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065360/
https://www.ncbi.nlm.nih.gov/pubmed/33865529
http://dx.doi.org/10.1016/j.ihj.2021.01.019
_version_ 1783682323711000576
author Yadava, O.P.
author_facet Yadava, O.P.
author_sort Yadava, O.P.
collection PubMed
description Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs. However, there is some light at the end of the tunnel for Digoxin, with the reporting of RATE-AF Trial at the recent European Society of Cardiology Congress. Compared to Bisoprolol, Digoxin use was associated with statistically significantly greater improvements in symptomatology and NT ProBNP levels making Digoxin a first line drug for rate control in permanent AF.
format Online
Article
Text
id pubmed-8065360
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-80653602021-04-27 ‘Digoxin conundrum – Time for validation?’ Yadava, O.P. Indian Heart J Opinion Paper Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs. However, there is some light at the end of the tunnel for Digoxin, with the reporting of RATE-AF Trial at the recent European Society of Cardiology Congress. Compared to Bisoprolol, Digoxin use was associated with statistically significantly greater improvements in symptomatology and NT ProBNP levels making Digoxin a first line drug for rate control in permanent AF. Elsevier 2021 2021-01-29 /pmc/articles/PMC8065360/ /pubmed/33865529 http://dx.doi.org/10.1016/j.ihj.2021.01.019 Text en © 2021 Cardiological Society of India. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Opinion Paper
Yadava, O.P.
‘Digoxin conundrum – Time for validation?’
title ‘Digoxin conundrum – Time for validation?’
title_full ‘Digoxin conundrum – Time for validation?’
title_fullStr ‘Digoxin conundrum – Time for validation?’
title_full_unstemmed ‘Digoxin conundrum – Time for validation?’
title_short ‘Digoxin conundrum – Time for validation?’
title_sort ‘digoxin conundrum – time for validation?’
topic Opinion Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065360/
https://www.ncbi.nlm.nih.gov/pubmed/33865529
http://dx.doi.org/10.1016/j.ihj.2021.01.019
work_keys_str_mv AT yadavaop digoxinconundrumtimeforvalidation

Ejemplares similares